Truist reiterates Buy on Alkermes stock, sees upside from data By Investing.com

Alkermes reported Q4 2025 EPS of $0.29 vs $0.41 expected (‑29.3% miss) while revenue modestly beat at $384.5M vs $383.07M. FY26 revenue guidance is $1.73–1.84B (consensus $1.80B) with net product sales guided to $1.52–1.60B; H.C. Wainwright trimmed its PT to $43 and kept a Neutral rating. Truist reiterated a Buy and $55 PT (~93% upside from $28.45), citing upcoming ORX750 data and oveporexton pricing/alixorexton launch as catalysts; the company also has more cash than debt and reported 87% gross margins.

Analysis

Class validation for orexin agonists materially changes the investment calculus: optionality shifts from a single binary (one compound proving efficacy) to a market-creation story that supports multiple entrants, larger indication sets, and licensing interest. That reduces idiosyncratic binary risk for the lead developer but also compresses monopoly pricing power—payers will have multiple negotiating levers once two or three agents reach the market.

Second-order winners include contract manufacturers, specialty pharmacies and diagnostic services that identify narcolepsy and hypersomnia patients; these supply-chain players face capacity and onboarding friction risks if uptake concentrates quickly, creating short-term bottlenecks that can slow revenue ramp despite strong clinical data. Conversely, legacy stimulant and sodium-oxybate based treatment providers face increased payer-driven step-therapy risk, which can materially flatten adoption curves and push realized revenue into later years.

Key risks and catalysts to watch: near-term clinical and pricing/launch-path disclosures that will reprice probability of peak revenue, payor coverage decisions that typically lag approval by quarters to years, and the potential for safety or manufacturing hiccups during scale-up. The path to material upside is multi-quarter and dependent on both label breadth and favourable formulary placement; the path to downside is quick if class pricing expectations are reset by payers or if a competing entrant secures preferential contracts with large PBMs. Timing is catalyst-driven (near-term readouts and the launch window over the next 12–24 months).

Key Decisions for Investors

• Long defined-risk ALKS call spread (9–15 month expiries): buy longer-dated calls and sell calls ~40–60% OTM to fund cost. Rationale: captures multiple catalysts (clinical readouts + launch/pricing cadence) with capped downside (max premium); target 2–3x if uptake/coverage tracks bullish models, max loss = premium paid.
• Calendar/diagonal for vega play: buy 15–24 month ALKS calls and sell 3–6 month calls near current strikes to finance position. Rationale: retains upside to a multi-quarter launch while collecting premium from short-term complacency; hedge by reducing net vega exposure ahead of headline readouts.
• Event hedge trade: purchase short-dated puts or put spreads around any upcoming clinical or pricing disclosures rather than naked short stock. Rationale: asymmetric protection for equity exposure—limits tail loss from negative readouts or adverse payer signals while preserving upside from positive class momentum.
• Pair trade (directional, 12 month): modest long ALKS equity position sized against a short position in a broad small-cap biotech ETF (e.g., XBI) to isolate company-specific upside while hedging sector beta. Rationale: captures company optionality from orexin franchise while protecting against sector-wide derisking or risk-off rotations.